AIM movers: Zanaga funding delays and Northern Bear share tender

EDX Medical (LON: EDX) has entered an agreement with Caris Life Sciences to make the Caris MI Clarity test that assesses short and long-term risk of breast cancer recurrence available in the UK. The share price increased 12.9% to 8.75p.

Building services provider Northern Bear (LON: NTBR) is launching a tender offer of up to £9.1m at 132.5p/share. Potential acquisitions have not been identified so the cash is being distributed to shareholders. Cash was £4.77m at the end of September 2026, while net cash was £3.8m. Pre-tax profit fell from £4m, which includes a non-recurring profit of £1.3m, to £2.05m. Market conditions are flat. The share price gained 10.2% to 129.5p.

– Advertisement –

Strategic communications services provider Aeorema Communications (LON: AEO) appears to be on a roll with another upgrade for 2026. Revenues guidance has been raised from £23m to at least £23.8m and underlying pre-tax profit will be £1.25m, against previous guidance of £1.06m, and well up on the 2025 figure of £437,000. Current projects have been increased in scope and recent projects generated better margins than anticipated. The share price is 8.57% higher at 95p.

Cadence Minerals (LON: KDNC) says that the 36.2% owned company that has the Amapa iron ore project in Brazil has been granted an operating licence for the Azteca processing plant. This triggers a $1.15m payment from the offtake facility. Production at Azteca is starting at a reduced rate. A first shipment of 45,000-48,000t of 65% iron concentrate is expected before the end of the year. A definitive feasibility study for the Amapa project will start next year. The share price rose 5.75% to 4.6p.

Localisation and media services provider Zoo Digital (LON: ZOO) had a strong first half helped by one-off programme catalogue subtitling contracts. Dubbing activity should increase in the second half as new programming comes through. The media services division was hit by a much lower contribution from the largest customer, which is restructuring. A recovery in demand from this customer is anticipated next year. Overall interim revenues were 6% ahead at $23.6m. Net cash was $1.5m. There was a profit of $777,000 in the period, compared to a $1.35m loss previously. The third quarter has started strongly, but there is unlikely to be as much one-off back catalogue work in the second half. Visibility is not good for the fourth quarter and there could be a second half loss. The share price improved 5.26% to 15p.

FALLERS

Zanaga Iron Ore Company (LON: ZIOC) says that the proposed investment in the Zanaga iron ore project by Red Arc Minerals is not likely to happen before the end of November. There are still areas where matters need to be agreed. The company will conduct a strategic review and seeking alternative finance while continuing go ahead with technical development of the project. The share price slumped 24.85 to 2.255p.

Cambridge Nutritional Sciences (LON: CNSL) interim revenues declined 39% to £2.4m due to weaker customer ordering in international markets and the health diagnostics business continues to be loss making. Gross margins have held up for and costs are being reduced. Forecast full year revenues have been cut from £6m to £5.5m, while the loss is expected to be similar to last year at £1m. A new IVDR-compliant FoodPrint product that will offer a broader range of food allergy tests is on course to be submitted for regulatory approval. The share price dipped 9.68% to 1.4p

Sabien Technology (LON: SNT) has secured a £100,000 working capital facility from Parris Group, which is controlled by Sabien Technology chief executive and 26.5% Richard Parris. The interest charge is 0.0822% each day on drawdowns – an annual rate of 30%. This is in addition to the previous £200,000 loan. The energy efficiency technology developer reported a decline in revenues from £850,000 to £750,000 in the year to June 2026 and remains loss making. The share price fell 8.33% to 2.75p.

Digital transformation services provider TPXimpact (LON: TPX) grew interim revenues from £36.2m to £57.9m, while pre-amortisation profit was £5.3m compared with £700,000 last time. The company has moved to a net cash position. TPXimpact continues to win contracts, but there are always concerns about government decision making and another spending review is happening next year. Digital should remain a focus of spending, though. The earnings estimate has been trimmed because of greater share dilution, but pre-tax profit is still expected to rise from £6.9m to £12.8m this year. The shares are trading on less than eleven times forecast earnings with potential upside if growth continues at the current rate. The share price declined 7.91% to 99p.